GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bullfrog AI Holdings BFRG · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.55

+6.39%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Bullfrog AI Holdings

From its filings with the US Securities and Exchange Commission

SEC filings

Bullfrog AI Holdings is based in Gaithersburg, Maryland and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker BFRG. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $116,670 and a net loss of $6.5m. At that date it held total assets of $2.8m and shareholders' equity of $2.1m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Health Care Technology
Listed since
14 Feb 2023
Employees
4
Head office
325 ELLINGTON BLVD., GAITHERSBURG, MD, 20878
Incorporated in
NV
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Vininder SinghChairman of the Board, Chief Executive Officer, since 2017$630,680
  • Mr. Joshua BlacherChief Financial Officer$10,631
  • Mr. R. Donald ElseyIndependent Director$79,050
  • Mr. William EnrightIndependent Director$79,050
  • Mr. Jason HansonIndependent Director$79,050
  • Mr. Rob FoleyVP - Investor Relations, since 2024

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • bfLEAP platform enables unbiased analysis of complex medical data sets in healthcare.
  • Therapeutic pipeline includes siRNA targeting Beta2-spectrin for HCC and obesity treatments.
  • Company employs 4 full-time staff focused on AI/ML-driven healthcare solutions.

Weaknesses

  • Limited employee count of 4 full-time staff restricts operational capacity.
  • IPO listing date 14 February 2023 indicates recent market entry.
  • Small therapeutic pipeline with only siRNA and Mebendazole products.

Opportunities

  • Growing demand for AI/ML in health care data analysis across the US market.
  • Potential expansion of therapeutic pipeline with siRNA and Mebendazole applications.
  • Translational R&D data sets from clinical trials offer new analysis opportunities.

Threats

  • Competition in health care AI sector from established US companies.
  • Regulatory challenges in medical data analysis within the US healthcare system.
  • Dependence on pre-clinical and clinical trial data for platform validation.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.